Abbott Receives U.S. FDA Approval for XIENCE nano to Treat Coronary Artery Disease in Small Vessels

Abbott ABT today announced it has received U.S. Food and Drug Administration approval for the XIENCE nano Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in small vessels. XIENCE nano, which is based on the same platform as the XIENCE V® Everolimus Eluting Coronary Stent System, offers physicians in the United States a new option for treating patients with coronary artery disease in vessels as small as 2.25 mm in diameter.